Present Change: Organogenesis (NASDAQ: ORGO)

Organogenesis is in the healthcare sector and is in the drug manufacturers industry. The company CEO is Gary S. Gillheeney. Avista Healthcare Public Acquisition Corp is a newly organized blank check company. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination.

Previous Intraday Performance:

The ORGO shares had a previous change of -0.41% which opened at 7.15 and closed at 7.27. It moved to an intraday high of 7.45 and a low of 7.13.

SeekingAlpha:  Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2019 Results – Earnings Call Transcript

Historical Performance:

Over the last five trading days, ORGO shares returned 2.83% and in the past 30 trading days it returned -7.86%. Over three months, it changed -28.66%. In one year it has changed -45.91% and within that year its 52 week high was 310.90 and its 52 week low was 6.28. ORGO stock is 15.76% above its 52 week low.

Our calculations result in a 50 day moving average of 7.34.

SeekingAlpha:  Organogenesis Holdings misses by $0.06, beats on revenue

Liquidity:

The company has a market cap of $663.9m with 91.3m shares outstanding and a float of 91.2m shares. Trading volume was 28,933 shares and has experienced an average volume of 45,931 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Organogenesis was -1.18 which ended on 31st of December 2018.

Below was the last reported quarterly diluted earnings per share:

1st Qtr 2019 -0.17
4th Qtr 2018 -0.12
3rd Qtr 2018 0.36
2nd Qtr 2018 -0.09
1st Qtr 2018 -0.35

The growth of the EPS is critical in understanding the current valuation of Organogenesis; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -51.50% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 1.30% of institutional ownership.

The beta was calculated to be -0.46.

SeekingAlpha:  Organogenesis Holdings misses by $0.06, beats on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -25.10%, profit margin is -66.15%, price-to-sales is 5.52 and price-to-book is 20.47.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 0  : Overall Result

Related

William Cook

William Cook

William Cook writes on current monetary and financial events. He is an entrepreneur and a writer. Cook holds a variety of distinctions counting the Chartered Financial Analyst (CFA) designation. He also holds an M.S. in Finance with a concentration in Investment Administration from Drexel University's Bennett S. LeBow College of Business. Cook also graduated magna cum laude from Dickinson College with a B.S. in Mathematics and a B.A. in Economics. 1414 Goldcliff Circle Alexandria, DC 22306

Leave a Reply

Your email address will not be published. Required fields are marked *